The role of staging in multiple myeloma

被引:0
|
作者
Yavorkovsky, Leonid L. [1 ]
机构
[1] Kaiser Permanente San Jose Med Ctr, Oncol Div, 271 Int Circle, San Jose, CA 95119 USA
关键词
Multiple myeloma; staging; risk stratification; prognosis; treatment; ADAPTED THERAPY MSMART; MAYO STRATIFICATION; RISK STRATIFICATION; DURIE-SALMON; R-ISS; SYSTEM; DIAGNOSIS; MANAGEMENT; CONSENSUS; SURVIVAL;
D O I
10.1080/17474086.2023.2277876
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The importance of cancer staging is determined by how accurately it can predict prognosis, and how useful it is for treatment decisions. Compared to other malignancies, multiple myeloma (MM) staging proved more challenging because of unreliable prognostic factors and wide-ranging life expectancy. As traditional MM staging continues to evolve, it requires reassessment of its prognostic and predictive value.Areas covered: The studies that included prognostic and predictive value of MM stages from 1975 through 2023 were selected for this review using PubMed, MEDLINE platforms. The history and evolution of MM staging are revisited, including its role in predicting survival, treatment planning and potential practical implications for the future. The role of MM staging for oncological practice and patient counseling is discussed.Expert opinion: The utility of the traditional MM staging remains unsatisfactory because it lacks a strong connection with the disease biology, prognosis or treatment planning. Additionally, it demonstrates a modest value for patient counseling because individual prognosis is subject to under- or overestimation, and the median survival or survival rates are difficult concepts to grasp. Although the role of MM stages may change in the future, the current research upholds the notion that MM staging benefits more medical research and clinical trials than oncological practice.
引用
收藏
页码:933 / 942
页数:10
相关论文
共 50 条
  • [41] The role of thalidomide in multiple myeloma
    Schwab, Chris
    Jagannath, Sundar
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (01): : 26 - 29
  • [42] Role of cytokines in multiple myeloma
    Anderson, KC
    Lust, JA
    SEMINARS IN HEMATOLOGY, 1999, 36 (01) : 14 - 20
  • [43] The role of MRD in multiple myeloma
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 241 - 241
  • [44] The role of bisphosphonates in multiple myeloma
    Kyle, RA
    ANNALS OF INTERNAL MEDICINE, 2000, 132 (09) : 734 - 736
  • [45] THE EXPRESSION OF APRIL BY MULTIPLE MYELOMA CELLS AND THEIR ROLE IN THE EVOLUTION OF MULTIPLE MYELOMA
    Xekalou, A.
    Kanellou, P.
    Vyzoukaki, R.
    Kokonozaki, M.
    Pappa, C.
    Devetzoglou, M.
    Sfyridaki, A.
    Psarakis, F.
    Alexandrakis, M.
    HAEMATOLOGICA, 2017, 102 : 781 - 781
  • [46] A simple additive staging system for newly diagnosed multiple myeloma
    Abdallah, Nadine H.
    Binder, Moritz
    Rajkumar, S. Vincent
    Greipp, Patricia T.
    Kapoor, Prashant
    Dispenzieri, Angela
    Gertz, Morie A.
    Baughn, Linda B.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Go, Ronald S.
    Hwa, Yi L.
    Fonder, Amie L.
    Hobbs, Miriam A.
    Lin, Yi
    Leung, Nelson
    Kourelis, Taxiarchis
    Warsame, Rahma
    Siddiqui, Mustaqeem A.
    Kyle, Robert A.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Ketterling, Rhett P.
    Kumar, Shaji K.
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [47] A simple additive staging system for newly diagnosed multiple myeloma
    Nadine H. Abdallah
    Moritz Binder
    S. Vincent Rajkumar
    Patricia T. Greipp
    Prashant Kapoor
    Angela Dispenzieri
    Morie A. Gertz
    Linda B. Baughn
    Martha Q. Lacy
    Suzanne R. Hayman
    Francis K. Buadi
    David Dingli
    Ronald S. Go
    Yi L. Hwa
    Amie L. Fonder
    Miriam A. Hobbs
    Yi Lin
    Nelson Leung
    Taxiarchis Kourelis
    Rahma Warsame
    Mustaqeem A. Siddiqui
    Robert A. Kyle
    P. Leif Bergsagel
    Rafael Fonseca
    Rhett P. Ketterling
    Shaji K. Kumar
    Blood Cancer Journal, 12
  • [48] Evaluation of five staging systems in 470 patients with multiple myeloma
    Mihou, Dimitra
    Katodritou, Irene
    Zervas, Kostas
    HAEMATOLOGICA, 2006, 91 (08) : 1149 - 1150
  • [49] EVALUATION OF PROGNOSTIC STAGING SYSTEMS FOR MULTIPLE MYELOMA IN THE ERA OF BORTEZOMIB
    Wee, N.
    Tan, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 614 - 614
  • [50] PROGNOSTIC SIGNIFICANCE OF THE REVISED INTERNATIONAL STAGING SYSTEM IN MULTIPLE MYELOMA
    Sretenovic, A.
    Bila, J.
    Jelicic, J.
    Fekete, M. Dencic
    Djurasinovic, V.
    Smiljanic, M.
    Vukovic, V.
    Antic, D.
    Andjelic, B.
    Todorovic, M.
    Mihaljevic, B.
    HAEMATOLOGICA, 2016, 101 : 545 - 546